H.C. Wainwright reiterates Avalo Therapeutics stock rating at buy
H.C. Wainwright reiterated a Buy rating and $30.00 price target for Avalo Therapeutics (NASDAQ:AVTX), which is trading near its 52-week low. The firm expects positive Phase 3 results from AbbVie's INTREPID study by mid-November or December 2026. Avalo has a strong balance sheet and upcoming FDA milestones in 2026-2027. Cantor Fitzgerald also reiterated an Overweight rating, citing IL-1 inhibition's potential. Three analysts recently raised earnings estimates.
How this was made
The 30-second read
Why it matters
The reiterated rating may provide slight support to the stock but does not create a clear trading trigger.
Market read
Low relevance; the piece offers no fresh information beyond an analyst rating repeat.
What to watch
Potential delays in Phase 3 readout or competitive advances in hidradenitis suppurativa treatments could dampen upside.
Background
Avalo Therapeutics is a clinical‑stage biotech developing IL‑1 inhibitors for hidradenitis suppurativa. The article repeats analyst coverage without new trial results.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $30 price target for Avalo Therapeutics (AVTX) and discussed upcoming Phase 3 trial expectations.
limited upside pressure as investors weigh trial prospects versus current low price.
The article provides no new data, only a rating reiteration and price target, which may influence sentiment but lacks a time‑sensitive trigger.
Market effects
None significant; the biotech sector remains unchanged.
No regional effect noted.
Limited to investors tracking early‑stage biotech trials.
Counterpoint
The reiterated Buy may be overly optimistic given the lack of new data and the stock's proximity to its 52‑week low.
Key entities
- companyAvalo Therapeutics
Biotech firm developing IL‑1 inhibitor therapies.
- analystH.C. Wainwright
Equity research firm that reiterated a Buy rating on AVTX.
